Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionFiera Capital Corp
Latest Disclosed Ownership78,822 shares
Latest Disclosed Value $ 26,079,836
Fiera Capital Corp reports 11.46% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Fiera Capital Corp filed a 13F-HR form disclosing ownership of 78,822 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $22,519,445 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 70,720 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 11.46% during the quarter. The current value of the position is $19,847,380 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 78,822 8,102 11.46 26,080 -7.26 0.0529
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70,720 16,916 31.44 28,122 14.62 0.0892
2025-11-07 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,804 26,061 93.94 24,535 171.21 0.0793
2025-08-08 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,743 10,531 61.18 9,047 94.66 0.0307
2025-05-07 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,212 1,242 7.78 4,648 23.69 0.0168
2025-01-29 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,970 15,970 3,758 0.0118
2021-08-16 2021-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -3,700 -100.00 0 -100.00
2021-05-11 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,700 185 5.26 522 14.22 0.0015
2021-02-09 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,515 800 29.47 457 15.70 0.0012
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,715 -340 -11.13 395 -12.61 0.0012
2020-08-07 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,055 3,055 452 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.